Skip to main content
. 2020 Oct 16;21(12):1803–1807. doi: 10.1016/j.jamda.2020.10.017

Fig. 2.

Fig. 2

(A) Single patient variation of COVID-19-HF score during the observation period and change of groups. GDMT, guideline-directed medical therapies; HDLD, Hight dose loop diuretics; LD, loop diuretics; PM, pacemaker; SCD, sudden cardiac death; TAVI, transcatheter aortic valve implantation. (B) Color groups variation at the end of the observation period (percentage of patients).